Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Incremental value in outcome prediction with gene expression-based signatures in diffuse large B-cell lymphoma.

Hong F, Kahl BS, Gray R.

Blood. 2013 Jan 3;121(1):156-8. doi: 10.1182/blood-2012-08-450106. Epub 2012 Nov 16.

2.

Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.

Stefancikova L, Moulis M, Fabian P, Vasova I, Zedek F, Ravcukova B, Muzik J, Kuglik P, Vranova V, Falkova I, Hrabalkova R, Smardova J.

Int J Oncol. 2011 Dec;39(6):1413-20. doi: 10.3892/ijo.2011.1170. Epub 2011 Aug 18.

PMID:
21874232
3.

Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP.

Testoni M, Kwee I, Greiner TC, Montes-Moreno S, Vose J, Chan WC, Chiappella A, Baldini L, Ferreri AJ, Gaidano G, Mian M, Zucca E, Bertoni F.

Br J Haematol. 2011 Oct;155(2):274-7. doi: 10.1111/j.1365-2141.2011.08675.x. Epub 2011 Apr 13. No abstract available.

PMID:
21488860
4.

Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi.

Merli F, Luminari S, Rossi G, Mammi C, Marcheselli L, Tucci A, Ilariucci F, Chiappella A, Musso M, Di Rocco A, Stelitano C, Alvarez I, Baldini L, Mazza P, Salvi F, Arcari A, Fragasso A, Gobbi PG, Liberati AM, Federico M.

Leuk Lymphoma. 2012 Apr;53(4):581-8. doi: 10.3109/10428194.2011.621565. Epub 2011 Nov 15.

PMID:
21895543
5.

The role of genotype in 104 cases of diffuse large B-cell lymphoma primary of breast.

Aviles A, Neri N, Nambo MJ.

Am J Clin Oncol. 2012 Apr;35(2):126-9. doi: 10.1097/COC.0b013e318209aa12.

PMID:
21325938
6.

Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.

Ruan J, Martin P, Furman RR, Lee SM, Cheung K, Vose JM, Lacasce A, Morrison J, Elstrom R, Ely S, Chadburn A, Cesarman E, Coleman M, Leonard JP.

J Clin Oncol. 2011 Feb 20;29(6):690-7. doi: 10.1200/JCO.2010.31.1142. Epub 2010 Dec 28.

PMID:
21189393
7.

Absolute lymphocyte count at day + 21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone.

Chae YS, Shin H, Sohn SK, Lee SJ, Moon JH, Kang BW, Kim JG, Yang DH, Lee JJ, Park TI.

Leuk Lymphoma. 2012 Sep;53(9):1757-63. doi: 10.3109/10428194.2012.670231. Epub 2012 Apr 19.

PMID:
22372848
8.

Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.

Malumbres R, Chen J, Tibshirani R, Johnson NA, Sehn LH, Natkunam Y, Briones J, Advani R, Connors JM, Byrne GE, Levy R, Gascoyne RD, Lossos IS.

Blood. 2008 Jun 15;111(12):5509-14. doi: 10.1182/blood-2008-02-136374. Epub 2008 Apr 29.

9.

New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma.

Frick M, Dörken B, Lenz G.

Best Pract Res Clin Haematol. 2012 Mar;25(1):3-12. doi: 10.1016/j.beha.2012.01.003. Epub 2012 Feb 8. Review.

PMID:
22409819
10.

Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma.

Giachelia M, Voso MT, Tisi MC, Martini M, Bozzoli V, Massini G, D'Aló F, Larocca LM, Leone G, Hohaus S.

Leuk Lymphoma. 2012 Mar;53(3):411-6. doi: 10.3109/10428194.2011.621566. Epub 2011 Oct 24.

PMID:
21902578
11.

BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.

Iqbal J, Meyer PN, Smith LM, Johnson NA, Vose JM, Greiner TC, Connors JM, Staudt LM, Rimsza L, Jaffe E, Rosenwald A, Ott G, Delabie J, Campo E, Braziel RM, Cook JR, Tubbs RR, Gascoyne RD, Armitage JO, Weisenburger DD, Chan WC.

Clin Cancer Res. 2011 Dec 15;17(24):7785-95. doi: 10.1158/1078-0432.CCR-11-0267. Epub 2011 Sep 20.

12.

Improving outcomes for patients with diffuse large B-cell lymphoma.

Flowers CR, Sinha R, Vose JM.

CA Cancer J Clin. 2010 Nov-Dec;60(6):393-408. doi: 10.3322/caac.20087. Epub 2010 Oct 28. Review.

13.

High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.

Li ZM, Huang JJ, Xia Y, Zhu YJ, Zhao W, Wei WX, Jiang WQ, Lin TY, Huang HQ, Guan ZZ.

Eur J Haematol. 2012 Jun;88(6):510-7. doi: 10.1111/j.1600-0609.2012.01778.x. Epub 2012 Mar 27.

PMID:
22413767
14.

Lymphotoxin alfa and receptor-interacting protein kinase 1 gene polymorphisms may correlate with prognosis in patients with diffuse large B cell lymphoma treated with R-CHOP.

Chae YS, Kim JG, Sohn SK, Moon JH, Kim SN, Lee SJ, Park TI, Lee MH.

Cancer Chemother Pharmacol. 2010 Feb;65(3):571-7. doi: 10.1007/s00280-009-1066-x. Epub 2009 Jul 24.

PMID:
19629486
15.

Stromal gene signatures in large-B-cell lymphomas.

Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project.

N Engl J Med. 2008 Nov 27;359(22):2313-23. doi: 10.1056/NEJMoa0802885.

16.

Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL.

Ott G, Ziepert M, Klapper W, Horn H, Szczepanowski M, Bernd HW, Thorns C, Feller AC, Lenze D, Hummel M, Stein H, Müller-Hermelink HK, Frank M, Hansmann ML, Barth TF, Möller P, Cogliatti S, Pfreundschuh M, Schmitz N, Trümper L, Loeffler M, Rosenwald A.

Blood. 2010 Dec 2;116(23):4916-25. doi: 10.1182/blood-2010-03-276766. Epub 2010 Aug 24.

18.

Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era.

Hasselblom S, Stenson M, Werlenius O, Sender M, Lewerin C, Hansson U, Nilsson-Ehle H, Andersson PO.

Leuk Lymphoma. 2012 Mar;53(3):394-9. doi: 10.3109/10428194.2011.616612. Epub 2011 Oct 10.

PMID:
21864039
19.

Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab.

Chaiwatanatorn K, Stamaratis G, Opeskin K, Firkin F, Nandurkar H.

Leuk Lymphoma. 2009 Oct;50(10):1666-75. doi: 10.1080/10428190903165233.

PMID:
19757311
20.

Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.

Papageorgiou SG, Diamantopoulos P, Levidou G, Angelopoulou MK, Economopoulou P, Efthimiou A, Constantinou N, Katsigiannis A, Korkolopoulou P, Pappa V, Economopoulou C, Georgiou G, Dimou M, Tsirigotis P, Kyrtsonis MC, Kotsianidis I, Kalpadakis C, Dimopoulos MA, Beris P, Meletis J, Pangalis GA, Dervenoulas J, Panayiotidis P, Vassilakopoulos TP.

Hematol Oncol. 2013 Mar;31(1):10-7. doi: 10.1002/hon.2012. Epub 2012 May 18.

PMID:
22610484

Supplemental Content

Support Center